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HealthcareAbstract Milk-derived bioactive peptides have been identiﬁed as potential ingredients of health-
promoting functional foods. These bioactive peptides are targeted at diet-related chronic diseases
especially the non-communicable diseases viz., obesity, cardiovascular diseases and diabetes.
Peptides derived from the milk of cow, goat, sheep, buffalo and camel exert multifunctional prop-
erties, including anti-microbial, immune modulatory, anti-oxidant, inhibitory effect on enzymes,
anti-thrombotic, and antagonistic activities against various toxic agents. Majority of those regulate
immunological, gastrointestinal, hormonal and neurological responses, thereby playing a vital role
in the prevention of cancer, osteoporosis, hypertension and other disorders as discussed in this
review. For the commercial production of such novel bioactive peptides large scale technologies
based on membrane separation and ion exchange chromatography methods have been developed.
Separation and identiﬁcation of those peptides and their pharmacodynamic parameters are neces-
sary to transfer their potent functional properties into food applications. The present review sum-
marizes the preliminary classes of bioactive milk-derived peptides along with their physiological
functions, general characteristics and potential applications in health-care.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Milk contains approximately 3.5% protein of which 80% are
casein and 20% whey proteins. Caseins have been classiﬁed
as a-, b- and k-caseins. Whey contains b-lactoglobulin, a-
lactalbumin and several minor proteins with different biologi-
cal activities such as enzymes, mineral-binding properties and
immunoglobulins. The multifunctional properties of biologi-
cally active milk peptides are increasingly acknowledged. It
could show a positive impact on human physiology and meta-
bolism either, directly or through enzymatic hydrolysis in vivo
or in vitro (Kitts and Weiler, 2003). The activity of peptides is
based on their inherent amino acid composition and sequence.
The size of bioactive peptide sequences known to possess
multifunctional properties may vary from two to twenty
amino acid residues (Meisel and Fitzgerald, 2003).
Biologically active peptides in the protein sequence are
deﬁned as fragments that remain inactive in precursor protein
sequences, but when released by the action of proteolytic
enzymes, they may interact with selected receptors and regu-
late the body’s physiological functions. The effect exerted by
such peptides may be positive or negative (Schlimme and
Meisel, 1995; Meisel and Bockelmann, 1999). Protease
enzymes are naturally occurring in food products, such as milk
plasmin, hydrolyze proteins and release bioactive fragments
during processing or storage. Many types of bacteria applied
in the production of fermented food products and occurring
naturally in the gastrointestinal tract are capable of producing
biologically active peptides. Cheese contains phospho peptides
which are further proteolyzed in the process of cheese ripening,
leading to the formation of various ACE inhibitors (Saito
et al., 2000).
Biologically active peptides derived from milk are initially
found in inactive form within the sequence of the precursor
molecules but it can be released in three ways; (i) enzymatic
hydrolysis with digestive enzymes like pepsin, trypsin, chy-
motrypsin etc; (ii) fermentation of milk with proteolytic starter
cultures; (iii) proteolysis by enzymes derived from proteolytic
microorganisms (Fig. 1) (Korhonen and Pihlanto, 2003).
Once these bioactive peptides are liberated, they may serve
to inﬂuence numerous physiological responses including car-
diovascular, digestive, endocrine, immune and neurologicalactivity etc. (Fig. 2). Because of such physiological versatility,
milk-derived bioactive peptides have drawn the attention of
many researchers worldwide in order to formulate several
potential drugs with nutraceutical supplement properties,
health promoting functional foods or other pharmaceutical
products (Korhonen and Pihlanto, 2003; FitzGerald and
Meisel, 2003). General characteristics of the primary classes
of bioactive milk peptides are discussed in this review.
2. Derivation of bioactive peptides
Milk peptides are derived from milk proteins by enzymatic
breakdown by digestive enzymes or by the proteinase enzymes
produced by lactobacilli during the fermentation of milk
(Jauhiainen and Korpela, 2007). Milk-derived bioactive pep-
tides are usually comprised of 2–20 amino acids and become
active after release from the precursor protein where they are
encrypted either by digestion or proteolysis both in vivo or
in vitro (Fig. 1).
2.1. Gastrointestinal digestion (in vivo)
Bioactive peptides may be released in vivo during gastrointesti-
nal digestion by the action of digestive enzymes like pepsin,
trypsin or chymotrypsin. Dietary proteins undergo denatura-
tion in the presence of hydrochloric acid (HCl) secreted by
the parietal cells of the stomach. This acid activates pepsinogen
and converts it into its active form, pepsin. Pepsin acts on pro-
teins to metabolise them to amino acids. Gastrointestinal diges-
tion permits the consequent action of the enzymes present in the
small intestine such as pepsin, trypsin or chymotrypsin, which
are responsible for protein hydrolysis (Korhonen and
Pihlanto, 2003). Several bioactive peptides (viz., anti-
bacterial, immunomodulatory, anti-hypertensive and opioid
peptides) are known to be released from casein and/or whey
proteins by gastrointestinal digestion (Meisel and Fitzgerald,
2003; Yamamoto et al., 2003; Fitzgerald et al., 2004;
Gobbetti et al., 2002, 2004). Some other proteolytic enzymes
such as alcalase, thermolysin, may be utilized with pepsin and
trypsin in order to simulate gastrointestinal digestion. They
have also been employed to release various bioactive peptides,
including CCPs (Mcdonagh and Fitzgerald, 1998), ACE
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Figure 1 Possible mechanisms for the release of bioactive peptides from dietary milk proteins.
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et al., 2014), anti-oxidative (Suetsuna et al., 2000; Rival et al.,
2001), immunomodulatory (Gauthier et al., 2006) and opioid
peptides (Pihlanto-Leppala et al., 1994, 1996).
2.2. Microbial fermentation (in vitro)
Several lactic acid bacteria (LAB) (e.g. Lactococcus lactis,
Lactobacillus helveticus) have been reported to release bioac-
tive peptides by the process of fermentation. This system con-
sists of a number of distinct intracellular peptidases including
endo-peptidases, amino-peptidases, di-peptidases, and tri-
peptidases (Christensen et al., 1999). Recent studies have
reviewed the production of various bioactive peptides includ-
ing antimicrobial, immunomodulatory, antioxidative and
ACE-inhibitory through microbial proteolysis (Gobbetti
et al., 2004; Korhonen and Pihlanto, 2003). The release of
bioactive peptides by fermentation of milk using different pro-
teolytic microorganisms or proteolytic enzymes derived from
such microorganisms has been summarized in Table 1.
2.3. Enzymatic activity
The most common way to produce bioactive peptides from
milk is through enzymatic hydrolysis of the whole proteinmolecules. Digestive enzymes and combinations of different
proteinases including alcalase, chymotrypsin, pepsin and ther-
molysin as well as enzymes from bacterial and fungal sources
have also been utilized to generate bioactive peptides from
various proteins.
3. Bioactive peptides and their role in human health
3.1. Antimicrobial peptides
Antimicrobial bioactive peptides derived from milk have been
reported to inhibit many Gram positive and Gram negative
pathogens including Escherichia coli MTCC82, Aeromonas
hydrophila ATCC7966, Salmonella typhi MTCC3216, Bacillus
cereus ATCC10702, Salmonella typhimurium SB300, S. enteri-
tidis 125109, Staphylococcus aureusMTCC 96 (Mohanty et al.,
2014) and control many microbial infections. In a similar way
chymosin digested casein releases caseicidin peptide that exhi-
bits antimicrobial activity against Staphylococcus spp., Sarcina
spp., Bacillus subtilis, Streptococcus pyogenes (Lahov and
Regelson, 1996). Several such peptides have been detected
and some of them are listed in Table 2. A cationic fragment
of casein, casocidin-I, is able to inhibit growth of E. coli and
S. Carnosus (Zucht et al., 1995) where as two other peptides
are isolated from the same casein, namely f183–207 and
Table 1 Bioactive peptides released from milk proteins by various microorganisms.
Microorganism Precursor
protein
Peptide sequence Bioactivity
L. rhamnosus+ digestion with
pepsin
b-cn Asp-Lys-Ile-His-Pro-Phe, Tyr-Gln-Glu-Pro- Val-Leu ACE inhibitory
Lactobacillus helveticus b-cn, j-cn Val-Pro-Pro, Ile-Pro-Pro ACE inhibitory,
antihypertensive
Lactobacillus GG enzymes + pepsin
and trypsin
b-cn, as1-cn Tyr-Pro-Phe-Pro, Ala-Val-Pro-Tyr-Pro-Gln Arg,
Thr-Thr-Met-Pro-Leu-Trp
Opioid, ACE-inhibitory,
immune-stimulatory
Lactobacillus delbrueckii subsp.,
bulgaricus IFO13953
j-cn Ala-Arg-His-Pro-His-Pro-His-Leu-Ser-Phe-met Antioxidative
Kluyveromyces marxianus var. b-lg Tyr-Leu-Leu-Phe ACE-inhibitory
Lactobacillus helveticus CP90
proteinase
b-cn Lys-Val-Leu-Pro-Val-Pro-(Glu) ACE-inhibitory
Table 2 Anti-microbial peptides derived from milk and their target microorganisms.
Milk peptides Protease Pathogens
Isracidin as1-CN (f1–23) Chymosin,
chymotrypsin
Staphylococcus aureus
Casecidin as1 and j-CN Chymosin,
chymotrypsin
Staphylococcus, Bacillus subtilis, Diplococcus pneumonia, Streptococcus pyogenes
Lactoferricin B and
Lactoferrin (f 17–41)
Pepsin Bacillus, E. coli, Candida albicans, Listeria, Streptococci, Klebsiella, Staphylococci,
Proteus, Pseudomonas, Salmonella
b-Casein derived peptides Trypsin and
chymotrypsin
Enterococcus faecium, Bacillus megaterium
580 D.P. Mohanty et al.f164–179 also able to inhibit pathogens (Recio and Visser,
1999). Lactoferrampin, isolated as a fragment of lactoferrin
displays inhibitory activity against Streptococcus mutans,
E. coli, B. subtilis and Pseudomonas aeruginosa (Van der
Kraan et al., 2004). Researchers have recognized new antibac-
terial peptides from a chymosin, trypsin digest of as2-CN
bovine, namely, Isracidine, which has a strong protective effect
against S. aureus, S. pyogenes and Listeria monocytogenes
(Lahov and Regelson, 1996). Glyco-macropeptide (GMP)
and caseinomacropeptide (CMP) are formed after a speciﬁc
cleavage of casein by chymosin (Farrell et al., 2004).
Caseinomacropeptide (CMP) may have an inhibitory activity
against S. mutans and E. coli whereas GMP modulates the
gut microﬂora (Manso and Lo´pez-Fandin˜o, 2004). Isfracidin
and lactoferricin B are effective against Candida albicans
(Bellamy et al., 1993; Lahov and Regelson, 1996).
Lactoferrin and its derivatives show the antibacterial
activity in vitro against various pathogens, e.g. Clostridium
perfringens, C. albicans, Haemophilus inﬂuenzae, Helicobacter
pylori, L. monocytogenes, P. aeruginosa, Salmonella enteritidis,
S. aureus, Vibrio cholerae as well as antiviral activity
against hepatitis C,G and B virus HIV-1, poliovirus,
rotavirus and herpes simplex virus (Farnaud and Evans,
2003; Pan et al., 2007).
3.2. Immunomodulatory peptides
Glycopeptides, hormones and peptide fragments of
immunoglobulins are usually considered as immunomodula-
tory peptides that regulate cell-mediated and humoral immune
functions. Later on, several other peptides were reported frombovine b-casein, which were responsible for phagocytizes in
humans and inhibited Klebsiella pneumoniae infection in mice
in vivo (Migliore-Samour and Jolle`s, 1988). More recently
many cyto-chemical studies indicate that the immunomodula-
tory bioactive peptides derived from both casein and whey
proteins are related to the stimulation and proliferation of
human lymphocytes, macrophage phagocytic activity, anti-
body synthesis and cytokine regulation (Clare et al., 2003;
Gill et al., 2000). Cytomodulatory peptides produced from
casein may inhibit cancer cell growth by stimulating the activ-
ity of immune competent cells (Meisel and Fitzgerald, 2003).
Glycomacropeptide (GMP) and its derivatives have been
revealed to be essential immunomodulatory functions includ-
ing immune suppressive effects on the production of IgG anti-
bodies (Monnai et al., 1998; Manso and Lo´pez-Fandin˜o,
2004). Lactoferrin is digested to form Lactoferricin B which
directly binds to neutrophils and show an opsonin like activity.
Other peptides such as f(63–680) and f(191–193) from bovine
b-casein may affect phagocytizes in humans in vitro
(Migliore-Samour and Jolle`s, 1988) where as some other pep-
tides from j-casein and a-lactalbumin are used in immune
therapy of human immune deﬁciency virus infection
(Hadden, 1991). Caseinomacropeptide (CMP) promotes the
growth of biﬁdobacteria or lactobacilli that inhibit enteric
infection (Bruck et al., 2003).
3.3. Anti-hypertensive peptides or angiotensin-converting enzyme
(ACE) inhibitory peptides
ACE is a peptidyl di-peptidase enzyme having the capacity to
cleave the carboxyl terminal end of the substrate that may
Table 3 Anti-oxidative peptides derived from milk proteins.
Protein source Enzyme Peptide sequence Antioxidative activity References
Casein Trypsin Val-Lys-Glu-Ala-Met-Ala-Pro-Lys Inhibition of enzymatic and
non-enzymatic lipid
peroxidation
Suetsuna et al.
(2000)
Casein Pepsin Tyr-Phe-Tyr-Pro-Glu-Leu Radical scavenging activity Rival et al.
(2001)
b-Lactoglobulin
(b-lg)
Corolase Trp-Tyr-Ser-Leu-Ala-Met-Ala-Ala-Ser-Asp-Ile Trp-Tyr-
Ser-Leu-Ala-Met-Ala-Ala-Ser-Asp-Ile Tyr-Val-Glu-Glu-Leu
Radical scavenging activity
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sin I to an active peptide hormone angiotensin II. This stimu-
lates the release of aldosterone, as a result of which sodium
concentration becomes high and blood pressure goes up. But
antihypertensive peptide is able to inhibit ACE to control
increase of blood pressure (Korhonen and Pihlanto, 2007).
ACE inhibitors are di- or tri-peptides containing proline,
lysine or arginine at their C-terminal end. Bioactive amino
acid sequence displaying antihypertensive activity is mainly
isolated from bovine and human caseins. Whey proteins
derived by the activity of lactic acid bacteria like L. helveticus,
L. lactis are resistant to the digestive tract endo-peptidases,
therefore, can be easily absorbed to the blood stream (Saito
et al., 2000). ACE inhibitory peptides such as b-casein,
j-casein have been isolated from enzymatic digest of sour milk
proteins as1 and b-CN (Bracquart and Lorient, 1979). In
addition to casein derived peptide, ACE inhibitory peptides
such as a-lactorphin and b-lactorphin are also generated
from whey proteins a-lactalbumin and lactoglobulin,
respectively (Maruyama and Suzuki, 1982; Maruyama et al.,
1985, 1987). The peptides Glu-Met-Pro-Phe-Pro-Lys and
Tyr-Pro-Val-Glu-Pro-Phe-Thr-Glu originate from the casein
sequences, f(108–113) and f(114–121); the latter showed an
in vitro inhibition effect upon ACE (Perpetuo et al., 2003).
ACE inhibitor peptides are food derived natural preventives
used to control hypertension and could lead to a decrease in
the requirement of medicines which exert strong side effects.
3.4. Opioid peptides
Opioid peptides are opioid receptor ligands which are
encrypted from bovine and human b-casein enzymatically
in vitro (Brantl, 1984) and also found to be present in the
endocrine, nervous and immune systems as well as the gas-
trointestinal tract of mammals. They interact with their
endogenous ligands and with exogenous and/or antagonist
opioids and may inﬂuence the central or peripheral nervous
systems which are involved in hypotension, lack of appetite,
ﬂuctuating body temperature and alteration of sexual behav-
iors (Molina and Abumrad, 1994; Dziuba et al., 1999).
Endogenous opioid agonist peptides may regulate the growth
and function of cells involved in the central nervous system
whereas b-casomorphins are transported across mucosal mem-
branes of neonates that regulate physiological responses result-
ing in calmness and sleep in infants (Calvo et al., 2000; Sturner
and Chang, 1988). On other hand, b-casomorphin interacts
with opiate receptors in the serosal side of the intestinal epithe-
lium and plays a crucial role in certain activities like regulationof electrolyte transport, insulin secretion and food absorption
(Tome and Debabbi, 1998). Opioid antagonists are able to
suppress the agonist activity of enkephalin. Two most useful
agonistic opioid peptides known as Serorphine and Casoxin
C have been isolated from f(399–404) fragments of bovine
serum albumin and bovine j-CN receptor respectively
(Meisel and Fitzgerald, 2000). There are several accumulating
evidences suggesting that two bovine casoxins (casoxins A and
B) are opioid receptor ligands that have relatively low antago-
nistic potency (Meisel, 1998). Casoxins A and B correspond to
amino-acid sequences within bovine k-casein; casoxin A is
accounted for by f(35–41) of k-casein (i.e. Tyr-Pro-Ser-Tyr-
Gly-Leu-Asn) corresponds to, whereas casoxin B corresponds
to f58–61 of k-casein (i.e. Tyr-Pro-Tyr-Tyr). Lastly, casoxin C
is a potent opioid antagonist peptide of k-casein f(25–34) (i.e.
Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg), possesses the high-
est biological potency (Xu, 1998). Presently, data suggest that
casomorphins, as opioid ligands, exert anti-secretory action
(Daniel et al., 1990), stimulate analgesic behavior (Matthies
et al., 1984) and endocrine responses such as secretion of
insulin and somatostatin (Meisel and Schlimme, 1990).
3.5. Antioxidant peptides
Several milk peptides also play a regulatory role in oxidative
metabolism which is essential for the survival of cells and
causes oxidative changes by producing free radicals. But when
an excess of free radicals is released, they oxidize cellular pro-
tein, membrane lipid, DNA, and enzymes that cause shutting
down of cellular respiration and mediate injuries including
atherosclerosis, diabetes, rheumatoid arthritis and oxidative
DNA-damage leading to cancer (Abuja and Albertini, 2001;
Halliwell, 2000; Halliwell and Whiteman, 2004). Moreover,
milk-derived anti-oxidative peptides are comprised of ﬁve to
eleven hydrophobic amino acids including proline, histidine,
tyrosine or tryptophan in sequence which are widely dis-
tributed among caseins, soybean and gelatine in hydrolysis
by proteolytic enzymes (Korhonen and Pihlanto, 2003) as
shown in Table 3. They may function by scavenging or pre-
venting the formation of radicals (Cervato et al., 1999; Wong
and Kitts, 2003), particularly, free radicals released from
casein peptides may inﬂuence scavenging activity (Suetsuna
et al., 2000; Rival et al., 2001) and also inhibit enzymatic
and non-enzymatic lipid peroxidation. Extensive researches
on anti-oxidative peptides have revealed that, the artiﬁcial
antioxidants provide strong antioxidant activity against sev-
eral oxidation systems. Because of their strong side effects on
human physiology and metabolism, these are restricted in
582 D.P. Mohanty et al.some countries and natural antioxidants have therefore been
developed from plants (Okada and Okada, 1998). Naturally
occurring vitamins (E and C), beta-carotene, and enzymatic
systems, mainly superoxide dismutase, catalase and glu-
tathione peroxidase have anti-oxidative activities (Lindmark-
Mansson and Kesson, 2000).
4. Conclusion
Bioactive peptides have attracted the interest of researchers as
a health promoting functional food. Yet there is limited work
done in this area due to lack of advanced technologies,
enriched products and molecular approaches. There is an
urgent need to focus on developing novel facilities including
advanced proteomics approaches, recombinant enzyme tech-
nologies and microbial fermentation, to study the various
impacts of bioactive peptides on expression of genes and also
to optimize the nutritional and health effects of these com-
pounds. Consequently allergenicity, toxicity and stability of
its biological functions during gastrointestinal digestion should
be tested in formulation of products incorporated with bioac-
tive peptides. Moreover, preliminary beneﬁcial effects of milk
derived bioactive peptides on target diseases should be consid-
ered carefully before it can be formulated as chemotherapeuti-
cal agents or may try to use them directly in their viable
condition. Hence separation and identiﬁcation of these pep-
tides and their pharmaco-dynamic parameters are necessary
to transfer their potent functional properties into food and
clinical applications. Scientiﬁc researches and industrial devel-
opment in the direction of searching novel bioactive peptides
promise to formulate several drugs and health beneﬁcial
functional foods.
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